HOME >> MEDICINE >> NEWS
IgG treatment during pregnancy reduces severity of rare, recurring liver condition in newborns

CHICAGO --- Treatment with high-dose immunoglobulin G (IgG) during pregnancy lessens the severity of hemochromatosis (NH), a rare, devastating gestational disease with abnormal iron accumulation in the liver and severe liver injury that almost always results in fetal death or acute liver failure in newborns.

In an article in the Nov. 6 issue of The Lancet, researchers Peter F. Whitington, M.D., and Judith U. Hibbard, M.D., described the effectiveness of treating mothers with IgG in reducing liver injury in babies with recurrent NH.

Whitington, a noted authority on liver disease, is professor of pediatrics at Northwestern University Feinberg School of Medicine, Children's Memorial Hospital. Hibbard is professor of maternal-fetal medicine, University of Illinois Chicago and held a similar position at the Pritzker School of Medicine, University of Chicago, during the course of the study.

One of the most devastating aspects of NH to affected families is that after a woman has had one baby with the disorder, her risk for recurrence of NH in another child is 80 percent. A woman may have unaffected children before having the first one with NH. After that, most or all pregnancies end with fetal death or a child born with NH.

Currently, there is no test to determine if a pregnancy will be affected, and there is no effective approach to prenatal diagnosis of NH. The best advice available to date for such women is to avoid pregnancy.

Until now, the cause of NH has been unknown. Whitington hypothesized that it is an alloimmune disease based on its unusual pattern of recurrence, which is similar to the known alloimmune diseases hydrops fetalis due to Rh incompatibility and neonatal alloimmune thrombocytopenia.

Treatment with IgG has been found effective in the treatment of these alloimmune blood disorders, so Whitington proposed its use in NH.

The positive results of the current study provide support for the th
'"/>

Contact: Elizabeth Crown or Kathleen Ellis
e-crown@northwestern.edu
312-503-8928
Northwestern University
9-Nov-2004


Page: 1 2

Related medicine news :

1. Hormonal treatment improves survival in high-risk prostate cancer patients
2. Chronic pain treatments more effective when taken together, new study shows
3. Brain activity prior to treatment flags vulnerability to antidepressant side effects
4. Cultural and social factors influence prostate cancer treatment
5. Research offers hope of new treatments for liver damage
6. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
7. Stanford patient is first to test new treatment for peripheral arterial disease
8. Scientist works on innovative treatments for brain tumors
9. Blacks less likely to get expensive, newer heart treatments
10. Growth hormone treatment improves symptoms of metabolic disorder in postmenopausal women
11. Study examines lessons learned at Africas first public antiretroviral treatment clinic

Post Your Comments:
(Date:7/31/2015)... ... July 31, 2015 , ... M3 USA MDLinx.com, source of the Smartest Doc ... Exam Courses. , The additions of Gastroenterology, Pulmonology and Allergy/Immunology round out an ... preparing for the exam easy and painless. MDLinx offers thousands of board-exam style ...
(Date:7/31/2015)... CA (PRWEB) , ... July 31, 2015 , ... According to the article ... floor of the Pasadena courthouse was contained and extinguished by the city’s fire department before ... in the building at the time of the fire, and it was a fire alarm ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Well-known for its ... offering wedding cakes with custom designs, making life just a little bit ... designed wedding cakes for each customer who orders one. , The bakery provides a ...
(Date:7/31/2015)... ... , ... Cosmetic Town has proven itself as the leader ... procedures including, but not limited to, abdominoplasty, blepharoplasty, rhinoplasty and septoplasty. The ... , Staying up to date with the latest cosmetic trends has never ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... a one-day event geared to patients and family members, medical professionals, and researchers, ... regional mesothelioma experts. The conference is a collaborative effort between the Mesothelioma Applied ...
Breaking Medicine News(10 mins):Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3
(Date:7/31/2015)... SAN DIEGO , July 31, 2015  Eisai ... Ltd. (Headquarters: Tokyo , President and ... Inc. (Headquarters: San Diego, California , ... HALO") have signed a clinical collaboration agreement to evaluate ... in combination with Halozyme,s investigational drug PEGPH20 (PEGylated recombinant ...
(Date:7/30/2015)... July 30, 2015 Edwards Lifesciences Corporation (NYSE: ... valves and hemodynamic monitoring, today announced that Robert A. ... "Bob is an ardent champion for innovation in ... to have him on Edwards, board as we pursue our ... chairman and CEO.  "Bob has provided a valuable perspective to ...
(Date:7/30/2015)... 2015  ResMed Inc. (NYSE: RMD ) today ...  Revenue for the quarter was $453.1 million, a 9 ... 2014 (a 17 percent increase on a constant currency ... quarter ended June 30, 2014.  Diluted earnings per share ... ended June 30, 2014.  The results ...
Breaking Medicine Technology:Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
Cached News: